Dr. Jeffrey Gold, UNMC’s chancellor, said the center will be the “linchpin” of many of the education and training activities that will take place at UNMC over the next half-century.
Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William (Bill) Daly, J.D., MBA, as Chief Business Officer and Keith H. Wells, Ph.D., as Chief Manufacturing Officer. Mr. Daly brings more than 30 years of broad experience in the biotech and pharma industry, covering business development, operations, finance, and strategy. Dr. Wells has been involved in the development of more than 90 vaccines and biopharmaceutical products, and most recently advised the Biomedical Advanced Research and Development Authority (BARDA) on the advanced development, licensure, and acquisition of medical countermeasures.
“The expansion of the leadership team comes at a pivotal time for Meissa as we are advancing one